Showing results (1331-1340 of 1,381) with videos related to
Sort By:
Pageof 139
The Journal of Clinical Investigation|June 9, 2026
Aberrant STAT signaling and T cell dysregulation define a targetable pediatric sepsis endotypeRobert B Lindell, Samir U Sayed, Jose S Campos Duran, et al.Biorxiv : the Preprint Server for Biology|May 11, 2021
Signaling through FcγRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19Sokratis A Apostolidis, Amrita Sarkar, Heather M Giannini, et al.Nature|February 3, 2022
Decade-long leukaemia remissions with persistence of CD4+ CAR T cellsJ Joseph Melenhorst, Gregory M Chen, Meng Wang, et al.Frontiers in Immunology|March 21, 2022
Signaling Through FcγRIIA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19Sokratis A Apostolidis, Amrita Sarkar, Heather M Giannini, et al.European Heart Journal. Digital Health|September 23, 2025
The hope and the hype of artificial intelligence for syncope managementSamuel L Johnston, E John Barsotti, Constantinos Bakogiannis, et al.The Lancet. Infectious Diseases|February 13, 2025
Targeting the SARS-CoV-2 reservoir in long COVIDAmy D Proal, Soo Aleman, Morgane Bomsel, et al.JAMA Cardiology|September 6, 2023
Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical TrialChristoffer Rasmus Vissing, Anna Axelsson Raja, Sharlene M Day, et al.Circulation. Heart Failure|December 10, 2019
Baseline Characteristics of the VANISH CohortAnna Axelsson Raja, Ling Shi, Sharlene M Day, et al.Cell|May 6, 2022
Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccineRishi R Goel, Mark M Painter, Kendall A Lundgreen, et al.Nature Medicine|September 24, 2021
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trialCarolyn Y Ho, Sharlene M Day, Anna Axelsson, et al.Pageof 139